Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
November 27 2023 - 8:55AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, will participate in a
special virtual event to discuss the current psychedelic
renaissance that is opening the doors to the benefits of both
traditional and novel psychedelics, as older therapies are being
re-examined and new molecules are being identified for current and
future clinical studies.
The virtual event will be held on Wednesday, Nov 29, 2023 at
12pm EST/ 9am PST. Register here.
The virtual event is part of The Psychedelic Association of
Canada (PAC) "Industry Presents" Series. The host for the event is
Gillian Maxwell, a PAC Board Member, that was a part of Canada’s
harm reduction and drug policy reform. She co-founded the Canadian
Drug Policy Coalition (CDPC) and served on the board of directors
of MAPS Canada for over 10 years.
The main guest for the virtual event will be Rick Doblin, PhD,
an American drug activist and executive who is the founder of the
Multidisciplinary Association for Psychedelic Studies (MAPS). His
professional goal is to help develop legal contexts for the
beneficial uses of psychedelics and marijuana, primarily as
prescription medicines.
Clearmind's CEO, Adi Zuloff-Shani, PhD, will share her thoughts
about the Company's innovative MEAI molecule, defined as novel
psychedelics. Mark Haden, MSW, VP of business development for
Clearmind Medicine, will take part in the event as well.
For additional information and registration, please visit
https://www.eventbrite.ca/e/traditional-vs-novel-psychedelics-tickets-746342519567?aff=oddtdtcreator.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fifteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations invest@clearmindmedicine.com Telephone: (604)
260-1566 US: CMND@crescendo-ir.com
General Inquiries Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Apr 2024 to May 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From May 2023 to May 2024